Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of teriparatide (FORTEO), which
is human parathyroid hormone 1-34, for increasing bone mass and improving bone structure in
adults affected with Osteogenesis Imperfecta (OI).
Phase:
Phase 4
Details
Lead Sponsor:
Oregon Health and Science University
Collaborators:
Eli Lilly and Company National Center for Research Resources (NCRR) National Institutes of Health (NIH) Osteogenesis Imperfecta Foundation